Evidence map›Paper›PMID 24038709›Full record

ArticleProtein science : a publication of the Protein Society2013

Amyloid fibril formation in vitro from halophilic metal binding protein: its high solubility and reversibility minimized formation of amorphous protein aggregations.

Yuhei Tokunaga, Mitsuharu Matsumoto, Masao Tokunaga, Tsutomu Arakawa, Yasushi Sugimoto

Open access · bronzeAbstract read
In one paragraph

Article in Protein science : a publication of the Protein Society, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Yuhei TokunagaLaboratory of Biochemstry and Bioscience, The United Graduate School of Agricultural Sciences, Kagoshima University, Korimoto, Kagoshima, 890-0065, Japan.
Mitsuharu Matsumoto
Masao Tokunaga
Tsutomu Arakawa
Yasushi Sugimoto
Kagoshima University · JPAlliance Protein Laboratories (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Halophilic proteins are characterized by high net negative charges and relatively small fraction of hydrophobic amino acids, rendering them aggregation resistant. These properties are also shared by histidine-rich metal binding protein (HP) from moderate halophile, Chromohalobacter salexigens, used in this study. Here, we examined how halophilic proteins form amyloid fibrils in vitro. His-tagged HP, incubated at pH 2.0 and 58°C, readily formed amyloid fibrils, as observed by thioflavin fluorescence, CD spectra, and transmission or atomic force microscopies. Under these low-pH harsh conditions, however, His-HP was promptly hydrolyzed to smaller peptides most likely responsible for rapid formation of amyloid fibril. Three major acid-hydrolyzed peptides were isolated from fibrils and turned out to readily form fibrils. The synthetic peptides predicted to form fibrils in these peptide sequences by Waltz software also formed fibrils. Amyloid fibril was also readily formed from full-length His-HP when incubated with 10-20% 2,2,2-trifluoroethanol at pH 7.8 and 25°C without peptide bond cleavage.

Indexed as

Amino Acid SequenceAmyloidBacterial ProteinsChromohalobacterCircular DichroismFluorescent DyesHumansMicroscopy, Atomic ForceMolecular Sequence DataPeptidesPeriplasmic Binding ProteinsProtein ConformationSoftwareTrifluoroethanolAmyloidBacterial ProteinsFluorescent Dyeshistidine-binding proteinPeptidesPeriplasmic Binding ProteinsTrifluoroethanol2,2,2,-trifluoroethanolacid-hydrolysisamyloid fibrilhalophilicsolubilitythioflavin

Identifiers

PMID24038709
PMCPMC3831673
OpenAlexW1495338696

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.